TokenPost topic

CERVINO Trial

1 TokenPost story is tagged CERVINO Trial. The newest appear first.

Latest CERVINO Trial stories

• AbbVie Seeks FDA Review of Etentamig for Relapsed or Refractory Myeloma

  In Phase 3 CERVINO, the response rate was 74.0% with etentamig and 45.7% with standard therapy after a median 11.4 months of follow-up.

  Oct 27, 2026, 10:25 PM EDT · Regulation